Neurobo Pharmaceuticals Reports First Patient Dosing in P-I Study of DA-1726 to Treat Obesity
Shots:
- NeuroBo has dosed the first patient in MAD part 2 (n=~36) of P-I study of DA-1726 in obese or healthy individuals with SAD part 1 involving 45 subjects. Topline data of SAD part 1 is anticipated in Q3’24 & MAD part 2 in Q1’25
- The 1EPs are safety & tolerability, 2EPs are PK in terms of serum concentrations & metabolite profiling at the highest dose and exploratory EPs are metabolic parameters, cardiac parameters, fasting lipid levels, body wt., waist circumference & BMI
- The recently secured funds of $70M will support the trial. Part 3 is expected, to find total wt. loss at 24wks., highest titratable dose & dietary changes; interim data is anticipated in mid-2026 & topline results in H2’26
Ref: NeuroBo | Image: NeuroBo
Related News:- NeuroBo Pharmaceuticals Reports IND Submission to the US FDA for Conducting P-I Study of DA-1726 to Treat Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
